Domača stranBNTX • NASDAQ
add
BioNTech
96,73 $
Po zaprtju:(0,00 %)0,00
96,73 $
Konec trgovanja: 3. dec., 16:00:50 GMT -5 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
96,11 $
Dnevni razpon
96,20 $ - 98,20 $
Letni razpon
81,20 $ - 129,27 $
Tržna kapitalizacija
23,26 mrd. USD
Povprečni obseg
923,82 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (EUR) | sep. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | 1,52 mrd. | 22,02 % |
Stroški poslovanja | 1,40 mrd. | 34,32 % |
Čisti dohodek | −28,70 mio. | −114,49 % |
Čista dobičkovnost prihodkov | −1,89 | −111,88 % |
Earnings per share | −0,12 | −114,81 % |
EBITDA | 91,20 mio. | 39,66 % |
Efektivna davčna stopnja | 216,19 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (EUR) | sep. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 14,53 mrd. | −13,06 % |
Skupna sredstva | 21,34 mrd. | −4,73 % |
Skupne obveznosti | 2,86 mrd. | −12,87 % |
Celoten lastniški kapital | 18,48 mrd. | — |
Shares outstanding | 240,46 mio. | — |
Razmerje P/B | 1,25 | — |
Donosnost sredstev | −0,38 % | — |
Donosnost kapitala | −0,44 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (EUR) | sep. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −28,70 mio. | −114,49 % |
Denar iz dejavnosti | 780,70 mio. | 222,19 % |
Denar iz naložb | −925,30 mio. | −551,16 % |
Denar iz financiranja | −11,50 mio. | −45,57 % |
Neto sprememba denarnih sredstev | −176,60 mio. | 76,52 % |
Prost denarni tok | 1,05 mrd. | 253,59 % |
Vizitka
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Generalni direktor
Datum ustanovitve
2008
Spletno mesto
Zaposleni
6.772
